Dose-Response Relationships of Inhaled Insulin Delivered via the Aerodose Insulin Inhaler and Subcutaneously Injected Insulin in Patients With Type 2 Diabetes
Diabetes Care2003Vol. 26(10), pp. 2842–2847
Citations Over TimeTop 10% of 2003 papers
Dennis Kim, Sunder Mudaliar, Sithipol Chinnapongse, Neelima V. Chu, Sarah M. Boies, Trent Davis, Ayesh D. Perera, Robert Fishman, Д. А. Шапиро, Robert R. Henry
Abstract
The overlapping dose-response curves of inhaled and subcutaneous treatments together with a consistent relative bioavailability and relative biopotency for inhaled insulin across doses suggest that the Aerodose insulin inhaler will deliver a pharmacologically predictable insulin dose to patients with diabetes similar to that observed following subcutaneous injection.
Related Papers
- → Continuous Glucose Monitoring Predicts Progression to Diabetes in Autoantibody Positive Children(2019)64 cited
- → Absorption, effectiveness and side effects of highly purified porcine NPH-insulin preparations (Leo�)(1978)33 cited
- → Comparative Study of Immunoactivity and Bioactivity of Sodium Insulin(1983)8 cited
- → Comparison between multi-injection and continuous subcutaneous insulin therapy in insulin-dependent diabetic inpatients(1981)8 cited
- → Exacerbation of asthma due to inadvertent use of a dummy inhaler(2018)